Michael Gelfand, MD
Epilepsy · Philadelphia, PANPI 1861706525
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $45,543 of the $50,067 with a category attached, or 91.0%. 14 manufacturers reported payments, led by UCB, Inc. at 48.9% of the total. Among epilepsy clinicians in PA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 50 payments — averaging $1001.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- UCB, Inc.$24K
- UCB SA$15K
- Livanova USA, Inc.$3K
- BTG International Inc.$3K
- Jazz Pharmaceuticals Inc.$2K
- Aquestive Therapeutics, Inc.$2K
- plus $2K from 8 others
Across 129 payments — averaging $8479.75 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- UCB SA$237K
- Eisai Inc.$207K
- SK Life Science, Inc.$151K
- Otsuka Pharmaceutical Development & Commercialization, Inc.$147K
- Aquestive Therapeutics, Inc.$128K
- Livanova USA, Inc.$104K
- plus $120K from 4 others
What the payments were for
- Consulting fees$45,54391%
- Speaking & faculty fees$2,3455%
- Travel & lodging$4391%
- Food & beverage$1,7403%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| UCB, Inc. | 21 | $24,460 |
| UCB SA | 10 | $15,000 |
| Livanova USA, Inc. | 2 | $2,840 |
| BTG International Inc. | 2 | $2,546 |
| Jazz Pharmaceuticals Inc. | 2 | $1,939 |
| Aquestive Therapeutics, Inc. | 2 | $1,680 |
| ZOLL Medical Corporation | 1 | $375 |
| Neurelis, Inc. | 3 | $306 |
| Greenwich Biosciences, Inc. | 2 | $283 |
| Neuropace, Inc. | 1 | $178 |
| Biogen | 1 | $150 |
| SK Life Science, Inc. | 1 | $144 |
| Amneal Pharmaceuticals LLC | 1 | $117 |
| Eisai Inc. | 1 | $50 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VNS Therapy$2,840
- Fintepla$2,784
- Epidiolex$2,176
- SYMPAZAN$840
- VALTOCO$228
- RNS Neurostimulator Kit$178
- TYSABRI$150
How this compares
$50,067 in reported general payments places this provider in the 90th percentile of 28 epilepsy providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FinteplaFenfluramine Hcl | 13 | $235,511 |
| EpidiolexCannabidiol (Cbd) | 28 | $228,298 |
| XcopriCenobamate | 97 | $199,262 |
| Lamotrigine ErLamotrigine | 178 | $74,298 |
| NayzilamMidazolam | 53 | $69,494 |
| OnfiClobazam | 11 | $58,675 |
| FycompaPerampanel | 21 | $37,110 |
| BriviactBrivaracetam | 15 | $36,076 |
| AptiomEslicarbazepine Acetate | 16 | $34,953 |
| Clobazam | 174 | $21,155 |
| Lacosamide | 122 | $16,000 |
| Levetiracetam ErLevetiracetam | 106 | $7,838 |
| Levetiracetam | 136 | $7,009 |
| Tegretol XrCarbamazepine | 12 | $5,159 |
| Divalproex Sodium ErDivalproex Sodium | 56 | $4,159 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| UCB, Inc.Fintepla, Nayzilam, Briviact | $24,460 | $341,08281 claims |
| SK Life Science, Inc.Xcopri | $144 | $199,26297 claims |
| Eisai Inc.Fycompa | $50 | $37,11021 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 28 epilepsy providers in Pennsylvania.
Other epilepsy in Philadelphia
- Kathryn DavisPhiladelphia$59K
- Saurabh SinhaPhiladelphia$21K
- Ramya RaghupathiPhiladelphia$14K
- Erin ConradPhiladelphia$3K
- Taneeta GangulyPhiladelphia$2K
- Catherine KulickPhiladelphia$2K
- Genna WaldmanPhiladelphia$2K
- Itai LoushyPhiladelphia$845
- Daniel ZhouPhiladelphia$658
- Brian LittPhiladelphia$384
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.